Healthy Skepticism Library item: 4284

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

MaLAM Letter follow up—Hoechst pentoxifylline
MaLAM Newsletter 1991 Aug

Abstract:

Hoechst has indicated that improvement in cognitive and mental function are not official recommended indications for pentoxifylline but rather than withdraw the claims the company cites flawed studies to support these claims.

Keywords:
*analysis/Indonesia/developing countries/pentoxifylline/neurologic drugs/Hoechst/company responses/quality of information/MaLAM/Medical Lobby for Appropriate Marketing/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/PROMOTION IN SPECIFIC THERAPEUTIC AREAS: NEUROLOGIC DISEASES/REGULATION, CODES, GUIDELINES: FEEDBACK TO COMPANIES